Breakthrough therapies. Establishes the breakthrough therapies research fund. Provides that a drug, biological product, or medical device that has been designated as a breakthrough therapy under federal law may be made available to a qualified patient and offered by a physician as a part of the patient's medical treatment. Specifies that a civil or criminal cause of action is not created against a manufacturer or health care provider for any harm to a qualified patient resulting from use of an investigational drug, biological product, or device.
| Authored by Representative Moed |
| Title | Description | Date | View |
|---|---|---|---|
| Fiscal Note | Fiscal Note #1: Introduced | 2024-01-08 | Click To View |
| Date | Chamber | Action |
|---|---|---|
| 2024-01-09 | House | First reading: referred to Committee on Public Health |
| 2024-01-09 | House | Authored by Representative Moed |
